Medicated Pain Relief Patches

Camphor, Menthol, Methyl Salicylate


Quality Choice (chain Drug Marketing Association)
Human Otc Drug
NDC 63868-124
Medicated Pain Relief Patches also known as Camphor, Menthol, Methyl Salicylate is a human otc drug labeled by 'Quality Choice (chain Drug Marketing Association)'. National Drug Code (NDC) number for Medicated Pain Relief Patches is 63868-124. This drug is available in dosage form of Patch. The names of the active, medicinal ingredients in Medicated Pain Relief Patches drug includes Camphor (synthetic) - 3.1 g/100g Menthol - 6 g/100g Methyl Salicylate - 10 g/100g . The currest status of Medicated Pain Relief Patches drug is Active.

Drug Information:

Drug NDC: 63868-124
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Medicated Pain Relief Patches
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Otc Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Camphor, Menthol, Methyl Salicylate
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Quality Choice (chain Drug Marketing Association)
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Patch
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:CAMPHOR (SYNTHETIC) - 3.1 g/100g
MENTHOL - 6 g/100g
METHYL SALICYLATE - 10 g/100g
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:TOPICAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: OTC MONOGRAPH NOT FINAL
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 01 Sep, 2017
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 16 Jan, 2025
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Application Number: part348
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:QUALITY CHOICE (Chain Drug Marketing Association)
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
RxCUI:1793147
The RxNorm Concept Unique Identifier. RxCUI is a unique number that describes a semantic concept about the drug product, including its ingredients, strength, and dose forms.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
UNII:5TJD82A1ET
L7T10EIP3A
LAV5U5022Y
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
63868-124-2020 PATCH in 1 BOX (63868-124-20) / 9 g in 1 PATCH01 Sep, 2017N/ANo
63868-124-6060 PATCH in 1 BOX (63868-124-60) / 9 g in 1 PATCH01 Sep, 2017N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Purpose:

Uses for temporary relief of minor aches and pains of muscles and joints associated with arthritis, simple backache, strains, sprains, and bruises.

Product Elements:

Medicated pain relief patches camphor, menthol, methyl salicylate camphor (synthetic) camphor (synthetic) menthol menthol methyl salicylate salicylic acid hydrogenated polydecene (550 mw) pentaerythritol tetrakis(3-(3,5-di-tert-butyl-4-hydroxyphenyl)propionate) liquid petroleum styrene/acrylamide copolymer (mw 500000)

Indications and Usage:

Indication and usage for temporary relief of minor aches and pains.

Warnings:

For external use only allergy alert: if prone to allergic reaction from asprin or salicylates, consult a doctor before use

Do Not Use:

For external use only allergy alert: if prone to allergic reaction from asprin or salicylates, consult a doctor before use

When Using:

When using this product use only as directed avoid contact with eyes, mucous membranes or rashes do not bandage tighly do not use at the same time as other topical analgesics dispose of used patch in manner that keeps product away from childrens and pets. used patches still contain the drug product that can produce serious adverse effects if a child or pet chews or ingests this patch.

Dosage and Administration:

Directions adults and children 12 years of age and over: clean and dry affected area. remove patch from film, apply to affected area not more than 3 to 4 times daily. remove patch from the skin after at most, 8-hour application. children under 12 years of age: consult physician. inactive ingredients hydrogenated poly, pentaerythrityl tetra-di-t-butyl hydroxyhydrocinnamate, petroleum, styrene / isoprene copolymer indication and usage for temporary relief of minor aches and pains.

Stop Use:

Stop use and consult a doctor if rash, itching or excessive skin irritation develops if condition worsens if symptoms last more than 7 days or clear up and occur again with a few days

Package Label Principal Display Panel:

Pain relief patch label other information : store in clean, dy place outside of direct sunlight. protect from excessive moisture. distributed by c.d.m.a., inc. 43157 w. nine mile novi, mi 48375 made in china box of 60

Further Questions:

Questions or comments customer care help line 248-449-9300 www.qualitychoice.com


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.